Innovation

Group in adaptation process:

Strategic Objectives

The Innovation Group comes under the Bioengineering Area, one of the seven research areas at the Biogipuzkoa HRI. It is made up of a group of associated researchers comprising representatives from different technological organisations, collaborating in a subject field that is not included in the priority areas of research, but whose development can lead to inclusion in any of the established groups or areas (Consolidated or Emerging).

The inter-disciplinary and multi-institutional collaboration model at the Biogipuzkoa HRI is evident in this group, which promotes translational health research with the purpose of improving people’s quality of life.

The main focus of research are micro and nano biotechnologies, biomaterials, molecular imaging, ICT and e-health, always aimed at innovation.

This group began with the 2009 Strategic Health Action plan in the RETICS [Cooperative Health Research Thematics Networks] sub-programme, the funding of which boosted the creation of the Institute’s Innovation Unit, whose purpose was to generate innovation in the non-pharmacological field of medical and health technologies as regards equipment, appliances, reactives, materials and ICT in health.

The drive given to collaborative translational research on a national and international level from this Group has led to a third of the Institute’s projects being carried out with a technology partner.

 

 

Team Members

Name Surname Center E-mail
Damien Dupin CIDETEC
ddupin@cidetec.es
Ion Lascurain Aguirrebena UPV/EHU ion.lascurain@ehu.eus
Iraida Loinaz Bordonabe CIDETEC iloinaz@cidetec.es
Ángela Moncada Pazos CIDETEC amoncada@cidetec.es

Scientific Output

RNA-MEM-INVESTIGACION DE TRATAMIENTOS PARA LA ENFERMEDAD DE ALZHEIMER MEDIANTE LA DEFINICION DE MODULADORES DE MODIFICACIONES DE ARN.
Código: KK-2023/00050
Investigador Principal (IP): MARCOS JESUS ARAUZO BRAVO
Entidad Financiadora: DEPARTAMENTO DE DESARROLLO ECONOMICO, SOSTENIBILIDAD Y MEDIO AMBIENTE
Fecha de Inicio: 2023-03-01
Fecha de finalización: 2024-12-31
Importe Concedido: 163.897,09 €
FACTORES PREDICTORES DE LA MEJORIA CON TRATAMIENTO CONSERVADOR DE FISIOTERAPIA EN PACIENTES CON CERVICALGIA CRONICA NO ESPECIFICA
Código: 2022111072
Investigador Principal (IP): ION LASCURAIN AGUIRREBENA
Entidad Financiadora: DEPARTAMENTO DE SALUD
Fecha de Inicio: 2022-11-02
Fecha de finalización: 2025-11-01
Importe Concedido: 74.532,06 €
IPERGLIO - IMPROVING PERSONALISED GLIOBLASTOMA CARE BY INTERTWINED IMMUNOMICS AND ARTIFICIAL INTELLIGENCE APPROACHES
Código: AC22/00043
Investigador Principal (IP): MARCOS JESUS ARAUZO BRAVO
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III; FUNDACION CIENTIFICA DE LA ASOCIACION ESPAÑOLA CONTRA EL CANCER
Fecha de Inicio: 2023-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 325.000,00 €
ENSAYO CLINICO ALEATORIZADO Y DOBLE CIEGO PARA VALORAR LA EFICACIA DEL ACIDO TRANEXAMICO EN LA REDUCCION DE LA PERDIDA SANGUINEA PACIENTES ANCIANOS CON FRACTURA DE CADERA
Código: ICI21/00084
Investigador Principal (IP): JOSU ARRIETA ALBERDI
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2022-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 182.875,00 €
NANOPARTICULES DE LIPOPROTEINES DE HAUTE DENSITE INTELLIGENTES POUR L'ADMINISTRATION CIBLEE D'INHIBITEURS DE LA TOR KINASE DANS LE LYMPHOME NON HODGKINIEN A CELLULES B. LYMPHOME NON HODGKINIEN A CELLULES B.
Código: PI21/01403
Investigador Principal (IP): SABRINA BRAZA
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2022-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 111.320,00 €